BioLineRx Ltd.
Healthcare / Biotechnology
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Performance
--
Today 0.00 (0.00%)
BLRX
Metrics
Market Cap12M
Latest Price$2.48
Previous Close$2.52
Volume69K
52 Week High$4.56
52 Week Low$2.15
52 Week Change-30.67%
Average Volume19K
Revenue1.4M
EPS0
Forward P/E-1.095
Price/Book0.92
Profit Margin0.00%
Operating Margin-6.30%
Return on Equity-0.47%
Dividend Yield0.00%